第 1 頁 共 2 頁 v 1.1.1 EF001 免責聲明 | 本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 | 香港小輪(集團)有限公司 | | 股份代號 | 00050 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二五年十二月三十一日止年度之末期股息 | | 公告日期 | 2026年3月19日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年12月31日 | | 宣派股息 | 每 股 0.15 HKD | | 股東批准日期 | 2026年5月29日 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.15 ...

香港交 易及結算所 有限公司 及 香港聯合交 易所有限 公司對本公 告的內容概 不負 責，對 其準確性或 完整 性亦 不 發表任何聲 明，並明確 表示，概不 對因本公 告全部或任 何部份內容 而產 生或因 倚賴該等內 容而 引致的任何損失承擔任何責任。 二零二五年業績公告 業績 於回顧年內，集團截至二零二五年十二月三十一日止年度溢利為港幣三億三千五百萬 元，較去年同期上升約百分之一百零九，主要原因為應佔合營發展項目「帝御」竣工結算 確認了一次性除稅後建築成本調整所致。 集團截至二零二五年十二月三十一日止年度基礎溢利為港幣二億八千四百萬元，較去年 同期上升約百分之八十。計及投資物業公允價值之變動，截至二零二五年十二月三十一 日止年度股東應佔溢利約為港幣三億三千五百萬元，較二零二四年同期增加約百分之一 百零五。 本年度每股盈利為港幣九角四仙（二零二四年：港幣四角六仙）。 綜合損益表 截至二零二五年十二月三十一日止年度 | | 二零二五年 | 二零二四年 | | --- | --- | --- | | | 港幣千元 | 港幣千元 | | 本年度溢利 | 334,728 | 160,376 | | 本年度其他全面收益 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而 引致的任何損失承擔任何責任。 HONG KONG FERRY (HOLDINGS) COMPANY LIMITED 香港小 輪（集 團 ）有 限公司 承董事會命 公司秘書 周東明 香港，二零二六年三月三日 於本公告日期，本公司之執行董事為林高演博士（主席）、李寧先生及李嘉豪先生（集團總經理）；非 執行董事為歐肇基先生；以及獨立非執行董事為何厚鏘先生、黃汝璞女士、胡經昌先生及陳惠仁先生。 ( 於香港註冊成立之有限公司 ) (股份代號: 50) 董事會召開日期 香港小輪（集團）有限公司（「本公司」）董事會（「董事會」）謹此宣佈，本公司將 於二零二六年三月十九日（星期四）舉行董事會會議，藉以（其中包括）批准刊發本公 司及其附屬公司截至二零二五年十二月三十一日止年度之全年業績公告及考慮派發末 期股息。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年2月28日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 香港小輪(集團)有限公司 | | | 呈交日期: | 2026年3月2日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.2.0 FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 00050 說明 已發行股份（不包括庫存股份）數目 庫存股份數目 已發行股份總數 上月底結存 356,273,883 0 356,273,883 增加 / 減少 (-) 0 0 本月底結存 356,273,883 0 356,273,883 足夠公眾持股量的確認(註4) | 根據《主板上市規則》第13.32D(1)條或第19A.28D(1)條 / 《GEM上市規則》第17.37D(1)條或第25.21D(1)條，我 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年1月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 香港小輪(集團)有限公司 | | | 呈交日期: | 2026年2月2日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 1. 股份分類 普通股 股份類別 不適用 於香港聯交所上市 (註1) 是 證券代號 (如上市) 00050 說明 已發行股份（不包括庫存股份）數目 庫存股份數目 已發行股份總數 上月底結存 356,273,883 0 356,273,883 增加 / 減少 (-) 0 0 本月底結存 356,273,883 0 356,273,883 足夠公眾持股量的確認(註4) | 根據《主板上市規則》第13.32D(1)條或第19A.28D(1)條 / 《GEM上市規則》第17.37D(1)條或第25.21D(1)條，我們在此確認，就上述所列股份類別而言，截至本月底: | ...

Core Viewpoint - *ST生物 has announced the termination of its major asset restructuring plan, which was initially aimed at acquiring a 51% stake in Hunan Huize Biomedical Technology Co., Ltd. The termination was agreed upon by all parties involved after failing to reach a substantial agreement during negotiations [1][3]. Group 1: Termination of Restructuring - The company disclosed the termination of the major asset restructuring plan on January 22, 2026, after multiple negotiations failed to yield an agreement [1][3]. - The restructuring plan was first announced on August 12, 2025, but did not progress to the formal implementation stage [1]. Group 2: Impact on Operations - The termination of the restructuring will not have a significant adverse impact on the company's current operations or financial status [3]. - The company maintains that the termination does not harm the interests of shareholders, particularly minority shareholders [3]. Group 3: Financial Performance Forecast - *ST生物 expects its 2025 revenue to be between 385 million to 425 million yuan, with a significant increase from approximately 130 million yuan in the previous year [3]. - The company forecasts a total profit of 18.5 million to 26.5 million yuan for 2025, with net profit attributable to shareholders expected to be between 28.5 million to 32.5 million yuan [3]. - All financial indicators are projected to show a turnaround, with net profit after excluding non-recurring gains and losses estimated between 8.5 million to 12.5 million yuan [3].

Core Viewpoint - *ST Bio (000504) expects significant revenue growth in 2025, projecting operating income between 385 million to 425 million yuan, compared to approximately 130 million yuan in the previous year, indicating a substantial year-on-year increase [2][5]. Financial Performance - The company anticipates a total profit of 18.5 million to 26.5 million yuan for 2025, with net profit attributable to shareholders expected to be between 28.5 million to 32.5 million yuan, and net profit after deducting non-recurring gains and losses projected at 8.5 million to 12.5 million yuan, all indicating a turnaround from previous losses [2][5]. - Basic earnings per share are forecasted to be between 0.025 yuan and 0.037 yuan, a recovery from a loss of 0.06 yuan per share in the previous year [5]. Revenue Drivers - The revenue increase is attributed to the acquisition of Loudi Jinhong New Materials Co., which enhanced the company's recycling business, particularly in the areas of waste battery and scrap steel recycling [5][6]. - The company has also expanded sales of related products in its main business, including beauty and health products linked to its biopharmaceutical operations, contributing to revenue and profit growth [5][6]. Cost Management - In 2025, *ST Bio implemented cost reduction and efficiency improvement measures, including organizational restructuring, personnel optimization, and expense control, which enhanced profitability [6]. Regulatory Context - 2025 is a critical year for *ST Bio to avoid delisting, as the company faced a risk warning due to negative profits and revenue below 300 million yuan in 2024 [7]. - The company can apply to lift the delisting risk warning if it meets specific financial criteria in the subsequent annual report [7]. Asset Restructuring - Concurrently, *ST Bio announced the termination of a major asset restructuring plan aimed at acquiring a 51% stake in Hunan Huize Biopharmaceutical Technology Co., a professional CRO company [11][12].

突发公告，终止筹划重大资产重组。 *ST生物（000504）1月22日晚间公告，公司于2025年8月12日披露了《关于筹划重大资产重组暨签署股 权收购意向协议的提示性公告》，拟收购程泽能、易木林、长沙君合致远企业管理咨询合伙企业（有限 合伙）、长沙市履方医药信息咨询合伙企业（有限合伙）合计持有的湖南慧泽生物医药科技有限公司 51%股权。本次筹划重组事项尚未进入正式实施阶段，交易各方未达成实质性协议，2026年1月22日公 司与交易各方签署了《股权收购意向协议之终止协议》。 公告称，自筹划重大资产重组事项以来，公司按照相关法律法规要求，积极推进本次重大资产重组的各 项工作。交易各方对本次重大资产重组交易方案进行了多次协商和谈判，未能最终达成一致。为切实维 护公司及全体股东利益，经公司审慎研究，并与交易各方友好协商，交易各方一致同意终止筹划本次交 易。 *ST生物称，终止本次交易系公司与相关各方经充分沟通、审慎分析及友好协商后作出的决定，各方就 本次交易终止无需承担任何违约责任。本次重大资产重组的终止，不会对公司现有生产经营活动、财务 状况产生重大不利影响。目前公司生产经营秩序正常，本次交易的终止不存在损害公司及 ...

Core Viewpoint - *ST Bio's major asset restructuring plan has failed, leading to the termination of the agreement to acquire 51% of Hunan Huize Biomedical Technology Co., Ltd. [1][6] Group 1: Restructuring Details - On January 22, 2026, *ST Bio signed a termination agreement for the acquisition of Hunan Huize Biomedical Technology Co., Ltd. [1][6] - The restructuring plan was initially announced on August 12, 2025, but did not progress to formal implementation due to a lack of substantial agreements among the parties involved [1][6][10] - The failure of the restructuring was attributed to unsuccessful negotiations and a lack of consensus among the transaction parties [10] Group 2: Company Background and Operations - *ST Bio primarily operates in the "biomedical" and "energy-saving and environmental protection" sectors, focusing on the production and sales of related products [3][8] - The company aims to enhance its profitability and risk resistance through the acquisition of Huize Biomedical, which specializes in drug research and clinical evaluation services [3][8] - Huize Biomedical has established long-term partnerships with over 300 pharmaceutical companies and research institutions, completing more than 1,000 technical service projects [3][8] Group 3: Financial Performance - *ST Bio has forecasted a net profit attributable to shareholders of 28.5 million to 32.5 million yuan for 2025, a significant recovery from a loss of 19.846 million yuan in the previous year [4][10] - The company has expanded its operations by acquiring and controlling Loudi Jinhong New Materials Co., Ltd., which has significantly boosted its revenue from recycling businesses [5][10] - The company has also diversified its product offerings, including sales of beauty and health products related to its biomedical business, contributing to revenue and profit growth [5][10]

智通财经APP讯，*ST生物(000504.SZ)公告，公司此前拟收购程泽能、易木林、长沙君合致远企业管理 咨询合伙企业(有限合伙)、长沙市履方医药信息咨询合伙企业(有限合伙)合计持有的湖南慧泽生物医药 科技有限公司51%股权。交易各方对本次重大资产重组交易方案进行了多次协商和谈判，未能最终达成 一致。交易各方一致同意终止筹划本次交易，2026年1月22日公司与交易各方签署了《股权收购意向协 议之终止协议》。 ...